MNA
LKFT

Manning & Napier Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Manning & Napier Advisors’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$721 Sell
25
-1
-4% -$33 ﹤0.01% 587
2025
Q4 		$848 Buy
+26
New +$839 ﹤0.01% 516

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Manning & Napier Advisors's LKFT Position: Q1 2026 in Review

Manning & Napier Advisors reduced its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 3.8% in Q1 2026, selling an estimated $33 and leaving 25 shares worth $721. The position accounts for ﹤0.01% of the portfolio, ranked #587.

Manning & Napier Advisors first reported a position in LKFT in Q4 2025 and has held it in 2 quarters since. The position peaked at $848 in Q4 2025. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

  • Manning & Napier Advisors held 25 shares of Lakefront Biotherapeutics American Depositary Shares worth $721 as of Q1 2026.
  • Manning & Napier Advisors sold 1 Lakefront Biotherapeutics American Depositary Shares share in Q1 2026, an estimated $33.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Manning & Napier Advisors's portfolio in Q1 2026, its #587 holding.
  • Manning & Napier Advisors first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2025 and has held it in 2 quarters since.
  • Manning & Napier Advisors's Lakefront Biotherapeutics American Depositary Shares position peaked at $848 in Q4 2025.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on Manning & Napier Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.